Free tool
FAERS Monitor: Myoview
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020372 or its brand name (Myoview, Technetium Tc-99m Tetrofosmin Kit). Reports on generic versions are filed under their own applications.
Reports
700
Serious
170
24% of reports
Hospitalization
55
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- no adverse event409
- radioisotope scan abnormal274
- drug ineffective152
- product quality issue29
- dizziness21
- headache21
- nausea20
- hypersensitivity16
- scan myocardial perfusion abnormal16
- urticaria16
- vomiting16
- dyspnoea15
- pruritus15
- chills12
- hyperhidrosis12
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 5 |
| 2006 | 5 |
| 2007 | 5 |
| 2008 | 9 |
| 2009 | 6 |
| 2010 | 9 |
| 2011 | 7 |
| 2012 | 6 |
| 2013 | 8 |
| 2014 | 17 |
| 2015 | 20 |
| 2016 | 35 |
| 2017 | 37 |
| 2018 | 36 |
| 2019 | 83 |
| 2020 | 91 |
| 2021 | 57 |
| 2022 | 38 |
| 2023 | 29 |
| 2024 | 28 |
| 2025 | 59 |
| 2026 | 106 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,459 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| radioisotope scan abnormalSignal | 274 | 19032.2 | 16679.9 | 3,181,922 |
| scan myocardial perfusion abnormalSignal | 16 | 3487.1 | 2089.2 | 46,894 |
| no adverse eventSignal | 409 | 68.0 | 63.8 | 27,097 |
| product quality issueSignal | 29 | 6.4 | 4.5 | 128 |
| drug ineffectiveSignal | 152 | 3.5 | 3.0 | 282 |
| chillsSignal | 12 | 3.1 | 1.8 | 15 |
| urticariaSignal | 16 | 2.9 | 1.8 | 18 |
| hyperhidrosisSignal | 12 | 2.8 | 1.6 | 12 |
| hypersensitivitySignal | 16 | 2.6 | 1.6 | 14 |
| dizziness | 21 | 1.3 | 0.8 | 1 |
| pruritus | 15 | 1.2 | 0.7 | 0 |
| vomiting | 16 | 1.0 | 0.6 | 0 |
| headache | 21 | 1.0 | 0.7 | 0 |
| dyspnoea | 15 | 0.8 | 0.5 | 1 |
| nausea | 20 | 0.8 | 0.5 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.